Combinations and uses thereof
US-11224654-B2 · Jan 18, 2022 · US
Combinations and uses thereof
US12194095B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12194095-B2 |
| Application number | US-202117545274-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 8, 2021 |
| Priority date | Aug 21, 2015 |
| Publication date | Jan 14, 2025 |
| Grant date | Jan 14, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
First claim
Opening claim text (preview).
We claim: 1. A method for treatment of non-Hodgkin's lymphoma in a patient in need thereof, said method comprising administering to the patient idelalisib and an antibody specific for CD19, wherein said antibody comprises: a variable heavy chain of the sequence (SEQ ID NO: 10) EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGY INPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGT YYYGTRVFDYWGQGTLVTVSS; a variable light chain of the sequence (SEQ ID NO: 11) DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQ LLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYP ITFGAGTKLEIK; a heavy chain constant domain of the sequence (SEQ ID NO: 12) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGK EYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK; and a light chain constant domain of the sequence (SEQ ID NO: 13) RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSG NSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVT KSFNRGEC. 2. The method of claim 1 , wherein said antibody specific for CD19 and idelalisib are administered separately. 3. The method of claim 1 , wherein said antibody specific for CD19 and idelalisib are administered separately physically. 4. The method of claim 1 , wherein said antibody specific for CD19 and idelalisib are administered separately in time. 5. The method of claim 1 , wherein said antibody specific for CD19 and idelalisib are administered together. 6. The method of claim 1 , wherein idelalisib is administered prior to administration of the antibody specific for CD19. 7. The method of claim 1 , wherein idelalisib is administered after administration of the antibody specific for CD19. 8. The method of claim 1 , wherein the non-Hodgkin's lymphoma is follicular lymphoma. 9. The method of claim 1 , wherein the non-Hodgkin's lymphoma is small lymphocytic lymphoma. 10. The method of claim 1 , wherein the non-Hodgkin's lymphoma is mucosa-associated lymphoid tissue lymphoma. 11. The method of claim 1 , wherein the non-Hodgkin's lymphoma is marginal zone lymphoma. 12. The method of claim 1 , wherein the non-Hodgkin's lymphoma is diffuse large B cell lymphoma. 13. The method of claim 1 , wherein the non-Hodgkin's lymphoma is Burkitt's lymphoma. 14. The method of claim 1 , wherein the non-Hodgkin's lymphoma is mantle cell lymphoma. 15. A method for treatment of chronic lymphocytic leukemia in a patient in need thereof, said method comprising administering to the patient idelalisib and an antibody specific for CD19, wherein said antibody comprises: a variable heavy chain of the sequence (SEQ ID NO: 10) EVQLVESGGGLVKPGGSLKLSCAASGYTFTSYVMHWVRQAPGKGLEWIGY INPYNDGTKYNEKFQGRVTISSDKSISTAYMELSSLRSEDTAMYYCARGT YYYGTRVFDYWGQGTLVTVSS; a variable light chain of the sequence (SEQ ID NO: 11) DIVMTQSPATLSLSPGERATLSCRSSKSLQNVNGNTYLYWFQQKPGQSPQ LLIYRMSNLNSGVPDRFSGSGSGTEFTLTISSLEPEDFAVYYCMQHLEYP ITFGAGTKLEIK; a heavy chain constant domain of the sequence (SEQ ID NO: 12) ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGV HTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP KSCDKTHTCPPCPAPELLGGPDVFLFPPKPKDTLMISRTPEVTCVVVDVS HEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGK EYKCKVSNKALPAPEEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTC LVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRW QQGNVFSCSVMHEALHNHYTQKSLSLSPGK;
Assignees
Inventors
Classifications
Complementarity determining region [CDR] · CPC title
two nitrogen atoms · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title
specific for leukemia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12194095B2 cover?
- The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.
- Who is the assignee on this patent?
- Incyte Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K39/395. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 14 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).